Analyst Price Targets — LBRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 9, 2026 9:26 am | — | Roth Capital | $31.00 | $20.80 | TheFly | LB Pharmaceuticals initiated with a Buy at Roth Capital |
| December 11, 2025 12:23 pm | — | Stifel Nicolaus | $35.00 | $21.36 | TheFly | LB Pharmaceuticals price target raised to $35 from $27 at Stifel |
| October 6, 2025 10:15 am | — | Leerink Partners | $34.00 | $15.05 | TheFly | LB Pharmaceuticals initiated with an Outperform at Leerink |
| October 6, 2025 9:15 am | — | Stifel Nicolaus | $27.00 | $15.05 | TheFly | LB Pharmaceuticals initiated with a Buy at Stifel |
Latest News for LBRX
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to…
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced that it has entered into a securities purchase agreement to sell 3,306,571 shares of its common stock and pre-funded warrants to purchase…
Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced…
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience…
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice President, Corporate Affairs and Lindsay Beaupre, the new Senior Vice President of People and Culture of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LBRX.
Senate Trading
No Senate trades found for LBRX.
U.S. House Trading
No House trades found for LBRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.